Shopping Cart
- Remove All
- Your shopping cart is currently empty
Dalmelitinib is a selective, orally active c-Met kinase inhibitor (IC50: 2.9 nM) that binds the ATP-binding region of c-Met. Dalmelitinib induces phosphorylation of MET and partially or completely inhibits phosphorylation of AKT and ERK. dalmelitinib exhibits a potent inhibitory effect on the proliferation of cancer cells (c-Met oncogene amplification) and can be used in cancer research (e.g. non-small cell lung cancer).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,140 | 6-8 weeks | |
50 mg | $2,785 | 6-8 weeks | |
100 mg | $3,520 | 6-8 weeks |
Description | Dalmelitinib is a selective, orally active c-Met kinase inhibitor (IC50: 2.9 nM) that binds the ATP-binding region of c-Met. Dalmelitinib induces phosphorylation of MET and partially or completely inhibits phosphorylation of AKT and ERK. dalmelitinib exhibits a potent inhibitory effect on the proliferation of cancer cells (c-Met oncogene amplification) and can be used in cancer research (e.g. non-small cell lung cancer). |
Molecular Weight | 461.47 |
Formula | C22H16FN7O2S |
Cas No. | 1637658-98-0 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.